Steve Yancey

2.5k total citations · 1 hit paper
37 papers, 1.6k citations indexed

About

Steve Yancey is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Steve Yancey has authored 37 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Physiology, 21 papers in Pulmonary and Respiratory Medicine and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Steve Yancey's work include Asthma and respiratory diseases (33 papers), Respiratory and Cough-Related Research (13 papers) and Inhalation and Respiratory Drug Delivery (12 papers). Steve Yancey is often cited by papers focused on Asthma and respiratory diseases (33 papers), Respiratory and Cough-Related Research (13 papers) and Inhalation and Respiratory Drug Delivery (12 papers). Steve Yancey collaborates with scholars based in United States, United Kingdom and Japan. Steve Yancey's co-authors include Héctor Ortega, Frank C. Albers, Mark Forshag, Anand A. Dalal, Stephen Mallett, Frank Moosig, Ulrich Specks, Judith C. Brown, Michael E. Wechsler and Praveen Akuthota and has published in prestigious journals such as New England Journal of Medicine, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.

In The Last Decade

Steve Yancey

36 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

2017 589 citations Michael E. Wechsler, Praveen Akuthota et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Steve Yancey

Since Specialization

Citations

This map shows the geographic impact of Steve Yancey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Yancey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Yancey more than expected).

Fields of papers citing papers by Steve Yancey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steve Yancey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Yancey. The network helps show where Steve Yancey may publish in the future.

Co-authorship network of co-authors of Steve Yancey

This figure shows the co-authorship network connecting the top 25 collaborators of Steve Yancey. A scholar is included among the top collaborators of Steve Yancey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steve Yancey. Steve Yancey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In‐depth sinus surgery analysis 2022 ·Allergy ·Wytske J. Fokkens, Joaquim Mullol, David W. Kennedy, Carl Philpott, Veronica Seccia, Robert C. Kern, A. Coste, Ana R. Sousa, Peter Howarth, Victoria S. Benson, Bhabita Mayer, Steve Yancey, Robert Chan, Simon Gane	24
2	Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count 2022 ·Journal of Allergy and Clinical Immunology ·Claus Bachert, Ana R. Sousa, Joseph K. Han, Rodney J. Schlosser, Leigh J. Sowerby, Claire Hopkins, Jorge Máspero, Steven G. Smith, (unknown), (unknown), Bhabita Mayer, Robert Chan, Steve Yancey, Adam Chaker	72
3	Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine 2020 ·The Journal of Allergy and Clinical Immunology In Practice ·Ian Pavord, Andrew Menzies‐Gow, Roland Buhl, Pascal Chanez, Mark T. Dransfield, Njira Lugogo, Oliver N. Keene, Eric Bradford, Steve Yancey	27
4	Fractional Exhaled Nitric Oxide and the Peripheral Blood Eosinophil Count as Biomarkers of the Response to Mepolizumab in Patients with Severe Eosinophilic Asthma 2018 ·American Journal of Respiratory and Critical Care Medicine ·Rahul Shrimanker, Ian Pavord, (unknown), Eric Bradford, Oliver N. Keene, Steve Yancey	2
5	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis breakdown → 2017 ·New England Journal of Medicine ·Michael E. Wechsler, Praveen Akuthota, David Jayne, Paneez Khoury, Amy D. Klion, Carol A. Langford, Peter A. Merkel, Frank Moosig, Ulrich Specks, María C. Cid, Raashid Luqmani, Judith C. Brown, Stephen Mallett, Richard Philipson, Steve Yancey, Jonathan Steinfeld, Peter F. Weller, Gerald J. Gleich	589
6	Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma 2016 ·Journal of Managed Care & Specialty Pharmacy ·Anand A. Dalal, Mei Sheng Duh, Laurence Gozalo, Marie-Noëlle Robitaille, Frank C. Albers, Steve Yancey, Héctor Ortega, Mark Forshag, Xiwu Lin, Patrick Lefèbvre	96
7	Acute and chronic systemic corticosteroid–related complications in patients with severe asthma 2015 ·Journal of Allergy and Clinical Immunology ·Patrick Lefèbvre, Mei Sheng Duh, Marie‐Hélène Lafeuille, Laurence Gozalo, Urvi Desai, Marie-Noëlle Robitaille, Frank C. Albers, Steve Yancey, Héctor Ortega, Mark Forshag, Xiwu Lin, Anand A. Dalal	158
8	Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma 2013 ·European Respiratory Journal ·Héctor Ortega, Lynn E. Katz, Benjamin Hartley, Steve Yancey	1
9	Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites 2013 ·Clinical Pharmacology in Drug Development ·Héctor Ortega, Steve Yancey, (unknown)	30
10	Controller medications and their effects on asthma exacerbations temporally associated with upper respiratory infections 2010 ·Respiratory Medicine ·Charlene M. Prazma, Kenneth M. Kral, (unknown), Steve Yancey, David A. Stempel	13
11	Ecologic analysis of asthma-related events and dispensing of inhaled corticosteroid- and salmeterol-containing products 2008 ·Annals of Allergy Asthma & Immunology ·Rachael L. DiSantostefano, Kourtney J. Davis, Steve Yancey, Courtney Crim	11
12	Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma? 2008 ·Respiratory Medicine ·Steven M. Koenig, John Murray, James Wolfe, (unknown), Steve Yancey, Barbara A. Prillaman, John L. Stauffer, Paul Dorinsky	22
13	Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone 2008 ·Current Medical Research and Opinion ·William C. Bailey, Mario Castro, Jonathan Matz, Martha V. White, Mark T. Dransfield, Steve Yancey, Héctor Ortega	33
14	Salmeterol response is not affected by β2-adrenergic receptor genotype in subjects with persistent asthma 2006 ·Journal of Allergy and Clinical Immunology ·Eugene R. Bleecker, Steve Yancey, Leslie Baitinger, Lisa Edwards, (unknown), Wayne H. Anderson, Paul Dorinsky	111
15	CONTROL OF AIRWAY INFLAMMATION IS ACHIEVED IN ASTHMA PATIENTS WITH FLUTICASONE PROPIONATE ALONE: ADDING MONTELUKAST PROVIDES NO ADDITIONAL CONTROL OF AIRWAY INFLAMMATION 2005 ·CHEST Journal ·Paul Dorinsky, Susan J. Wilson, Steve Yancey, Donna Reilly, John L. Stauffer, Lisa Edwards, (unknown), Ratko Djukanović	1
16	Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50μg Diskus® are “stepped-down” to fluticasone propionate, salmeterol or montelukast alone 2004 ·Journal of Allergy and Clinical Immunology ·(unknown), (unknown), Steve Yancey, Barbara A. Prillaman, Paul Dorinsky	8
17	Clinical Markers of Worsening Asthma With the Fluticasone Propionate/Salmeterol 100/50 mcg Diskus ® (FSC) vs Fluticasone propionate (FP) 250 mcg Alone in Patients Requiring FP 250 mcg BID for Asthma Stabilit 2003 ·CHEST Journal ·Paul Dorinsky, Steve Yancey, (unknown), Lisa Edwards	2
18	Reduction of asthma-related exacerbations and exacerbation-related costs during initial maintenance therapy with fluticasone propionate/salmerol combination product versus montelukast or fluticasone propionate alone 2003 ·Journal of Allergy and Clinical Immunology ·Richard H. Stanford, Paul Dorinsky, Courtney Crim, Steve Yancey, Lisa Edwards, Kathy Rickard	2
19	Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids. 2001 ·PubMed ·Harold S. Nelson, R.A. Nathan, Chris Kalberg, Steve Yancey, Kathy Rickard	31
20	One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma 2001 ·Journal of Allergy and Clinical Immunology ·David A. Stempel, Jay Meyer, Richard H. Stanford, Steve Yancey	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact